Each of the ten Distinguished Investigator Grants offers $100,000 for a one-year period, targeting projects that focus on a range of debilitating disorders such as depression, autism spectrum disorder (ASD), post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia, cocaine use disorder, and chronic cannabis use. This funding initiative is a vital component of WoodNext’s five-year $5 million commitment to BBRF’s programs, underscoring the priority placed on unearthing transformative insights into mental illness.

Jeffrey Borenstein, M.D., President and CEO of BBRF, emphasizes the urgency of these studies by highlighting the vast impact of mental illness globally and the persistent gaps in our biological understanding of these disorders. According to Dr. Borenstein, these grants facilitate research that challenges conventional paradigms, potentially redefining diagnostic criteria, enhancing monitoring techniques, and paving the way for innovative treatments that could significantly alter patient outcomes.

The WoodNext Foundation, led by Executive Director Nancy Chan, stresses the importance of supporting high-impact scientific endeavors that push the bounds of current knowledge. They believe that such bold research efforts are essential in unlocking novel therapeutic avenues and ultimately improving lives affected by mental health conditions.

Among the notable recipients, Dr. Ravi Allada from the University of Michigan is investigating the intricate biological interplay between bipolar disorder and the regulation of circadian rhythms and sleep. His work aims to identify biomarkers that could refine diagnosis and treatment – a thorough molecular mapping of risk genes to functional clinical phenotypes could revolutionize how the psychiatric community assesses and manages bipolar disorder, potentially integrating circadian-based therapeutic modalities such as timed light exposure and melatonin administration.

At Harvard University, Dr. Paola Arlotta leverages cutting-edge human brain organoid technology to model early developmental disruptions associated with ASD. By studying the asynchronous maturation of inhibitory neurons relative to their excitatory counterparts, her research delves into the cellular and circuit-level abnormalities that might underlie the diverse manifestations of autism across different genetic risk profiles. The project will test hypotheses regarding the neural circuitry disruption caused by mutations in genes such as ARID1b, deepening our understanding of ASD pathogenesis at a fundamental level.

Dr. Christopher W. Cowan from the Medical University of South Carolina is pioneering an RNA-based therapeutic approach to treat MEF2C haploinsufficiency syndrome (MCHS), a single-gene disorder with profound neurodevelopmental consequences including autism-like symptoms, language impairment, and seizures. His research not only sheds light on the molecular underpinnings of this rare but debilitating syndrome but also has broader implications for bipolar disorder, major depressive disorder, and schizophrenia, all of which show genetic correlation with MEF2C variants.

Addressing PTSD, Dr. Aline Desmedt at INSERM in France has innovated an animal model that accurately captures the dual facets of pathological trauma memory: traumatic hypermnesia and contextual amnesia. This critical distinction allows for a refined exploration of the neurobiological mechanisms regulating the transformation between normative fear memories and pathological trauma responses. Her work could illuminate novel targets for therapeutic intervention aimed at preventing or reversing the intrusive and debilitating memories characteristic of PTSD.

Cocaine use disorder (CUD) is the focus of Dr. Karen D. Ersche’s research at the University of Cambridge, where she investigates the role of neuroendocrine disruptions impacting decision-making and emotional regulation. This research explores how imbalances in the hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes influence brain regions such as the amygdala and orbitofrontal cortex. Understanding the link between hormonal dysregulation and maladaptive behaviors in CUD could herald new pharmacological or behavioral treatment strategies.

The intersection of gene expression and neuropsychiatric disorders is a frontier explored by Dr. Stephen J. Glatt at SUNY Upstate Medical University, who is developing BrainGENIE+, an advanced algorithm to non-invasively infer gene expression across multiple brain regions via blood samples. This methodological breakthrough promises not only to trace molecular dynamics during disease onset, progression, and recovery but also to establish comprehensive atlases of gene expression linked to brain health and pathology.

UCLA’s Dr. Alicia Izquierdo investigates the neurocircuitry underlying schizophrenia by dissecting how the brain distinguishes between environmental volatility—the rate at which external conditions change—and stochasticity, the random noise inherent in these conditions. Her focus on thalamo-frontocortical networks and their role in modulating these perceptions is expected to illuminate how impaired volatility processing contributes to paranoia and psychosis, offering new avenues for targeted neuromodulation therapies.

At the Medical University of South Carolina, Dr. Wei Jiang focuses on the paradoxical association of chronic cannabis use with anxiety, depression, and suicidality. His research zeroes in on the peripheral contributions to central nervous system dysfunction, particularly how alterations in the oral microbiome, specifically Actinomyces species, might drive mitochondrial dysfunction and disturbed neurotransmission, thus influencing emotional states in chronic users.

Dr. Loren L. Looger from UC San Diego explores an underappreciated pharmacological mechanism for antidepressant effects: the intracellular upregulation of serotonin synthesis. While selective serotonin reuptake inhibitors (SSRIs) act extracellularly, recent findings suggest psychedelics and MDMA may boost serotonin synthesis within neurons, enhancing therapeutic outcomes. Dr. Looger’s high-throughput screen aims to identify novel compounds that modulate this intracellular pathway, potentially revolutionizing antidepressant drug design beyond conventional modalities.

Finally, Dr. Jamie L. Maguire at Tufts University addresses the pressing issue of treatment-resistant depression by developing therapies targeting neurosteroid synthesis. These endogenous compounds possess documented anxiolytic and antidepressant properties, and by enhancing their biosynthesis, her team aims to craft transdiagnostic interventions with the potential to dramatically expand the therapeutic arsenal for psychiatric illnesses.

The BBRF and its Allied WoodNext Foundation collectively underscore a fundamental commitment: 100% of funds donated for research are reinvested exclusively into scientific projects, ensuring the most effective use of philanthropic resources. This model has empowered the Foundation to grant over $476 million to more than 5,700 investigators since 1987, fostering innovation and hope within the mental health community. Through sustained investment in high-risk, high-reward research, these grants propel the scientific community toward breakthroughs that could redefine mental health diagnostics, therapeutics, and ultimately, patient recovery worldwide.

Subject of Research: Neurobiological and behavioral research into major mental health disorders including depression, autism spectrum disorder, PTSD, bipolar disorder, schizophrenia, and substance use disorders.

Article Title: Brain & Behavior Research Foundation Awards $1 Million for Groundbreaking Mental Health Research in 2026

News Publication Date: Not specified

Web References:
– https://bbrfoundation.org/
– https://www.instagram.com/woodnext/
– https://www.pbs.org/show/healthy-minds-with-dr-jeffrey-borenstein/

Image Credits: BBRF

Keywords: Mental health, neurobiology, depression, autism spectrum disorder, PTSD, bipolar disorder, schizophrenia, cocaine use disorder, chronic cannabis use, circadian rhythms, gene expression, neurosteroids, serotonin synthesis, neuroendocrine dysregulation, brain organoids, RNA therapeutics

Each year, the BBRF convenes its Scientific Council, a collective of nearly 200 distinguished experts spanning various disciplines within brain and behavioral sciences, to meticulously evaluate the contributions of numerous candidates. This rigorous selection process ensures that awardees exemplify exceptional innovation and have a tangible impact on advancing mental health research. The 2025 prizewinners will share their cutting-edge findings at the upcoming BBRF International Mental Health Research Symposium, scheduled for October 24, 2025, at New York City’s Kaufman Music Center. The formal awards ceremony will follow that evening, further celebrating these leaders in psychiatric science.

One of the honored recipients, Dr. Daniel C. Javitt from the Nathan Kline Institute for Psychiatric Research and Columbia University, will receive the Lieber Prize for Outstanding Achievement in Schizophrenia Research. His pioneering presentation, “Listening to Schizophrenia: How Modern Neuroscience Explains the Subjective Experience of Schizophrenia and Points to New Treatment and Remediation Approaches,” promises to elucidate the neural mechanisms underlying the complex phenomenology of schizophrenia. By integrating contemporary neuroscience with clinical insights, Dr. Javitt aims to refine diagnostic frameworks and explore innovative remediation strategies to alleviate cognitive and perceptual disruptions characteristic of this disorder.

Complementing this effort, Dr. Antigona Martinez, also affiliated with Nathan Kline Institute and Columbia University, will be awarded the Maltz Prize for Innovative and Promising Schizophrenia Research. Her work centers on modulating specific brain circuits to enhance emotional recognition deficits in schizophrenia patients. Employing advanced neuroimaging techniques and circuit-based interventions, Dr. Martinez investigates how targeted manipulations within neural networks can restore social cognitive functions, which are crucial for daily interpersonal interactions and quality of life.

In the realm of mood disorders, Dr. Ole A. Andreassen of the University of Oslo and Oslo University Hospital will be recognized with the Colvin Prize for Outstanding Achievement in Mood Disorders Research. His research utilizes large-scale genetic analyses to uncover biological pathways implicated in bipolar disorder. Dr. Andreassen’s approach integrates genomics with clinical phenotyping, offering unprecedented insights that may translate into precision medicine. These discoveries hold potential for developing individualized therapies that directly target the molecular substrates of mood dysregulation.

The Ruane Prize for Outstanding Achievement in Child & Adolescent Psychiatric Research goes to Dr. Luis Augusto Paim Rohde, whose work at the Federal University of Rio Grande do Sul and affiliated institutions in Brazil focuses on attention-deficit/hyperactivity disorder (ADHD). His presentation, “What Can a Research Center in Brazil Tell Us About ADHD?” exemplifies how regional research centers can contribute valuable epidemiological and neurodevelopmental data in diverse populations, thereby enriching global perspectives on pediatric psychiatric conditions and informing cross-cultural diagnostic and treatment protocols.

Highlighting cognitive neuroscience, Dr. Joseph LeDoux of New York University and NYU Langone will receive the Goldman-Rakic Prize. His talk, “What Happened to the ‘Mental’ in ‘Mental’ Disorders?” challenges prevailing frameworks by revisiting the cognitive and emotional dimensions of psychiatric illnesses. Dr. LeDoux’s work intricately dissects the neural circuits involved in fear and anxiety, proposing refined models that bridge the gap between brain-based mechanisms and subjective mental experiences.

In addition to these scientific accolades, the Foundation will spotlight a humanitarian leader, Nur Yanayirah, founder of MotherHope Indonesia, who earned the 2025 Pardes Humanitarian Prize in Mental Health. Her presentation, “Empowering Maternal Voices Through Peer Support and Advocacy,” underscores the crucial role of community-driven mental health initiatives. By facilitating peer support networks and advocacy, Ms. Yanayirah’s efforts address maternal mental health challenges, which are often marginalized yet essential for broader societal well-being.

The Brain & Behavior Research Foundation has been a transformative force in psychiatric research funding since its inception in 1987. With over $475 million awarded to more than 5,700 scientists globally, the BBRF exclusively channels every donated dollar into research grants, thanks to separate grants covering operational costs. This financial model underscores a profound commitment to accelerating breakthroughs in conditions such as addiction, ADHD, anxiety, autism spectrum disorder, bipolar disorder, borderline personality disorder, depression, eating disorders, obsessive-compulsive disorder, PTSD, and schizophrenia.

Beyond funding, the BBRF is actively combating the stigma surrounding mental illness. It produces the Emmy®-nominated public television series “Healthy Minds with Dr. Jeffrey Borenstein,” which aims to demystify psychiatric disorders and promote hope through education. This multifaceted approach of supporting scientific inquiry while fostering public understanding exemplifies the Foundation’s holistic mission to transform mental health care worldwide.

The 2025 Outstanding Achievement Prizes signify more than just awards; they herald a new era of integrative, precise, and humane psychiatric research. Each recipient’s work embodies the cutting edge of neuroscience and psychiatry, combining molecular genetics, neuroimaging, cognitive psychology, and community health. Collectively, their contributions offer renewed optimism for developing effective interventions that will ultimately reduce the personal, social, and economic burdens imposed by mental illnesses.

As mental health conditions remain among the leading causes of disability globally, initiatives like those supported by the BBRF are critical. They fuel the scientific engine that moves us closer to unraveling the complexity of brain disorders and establishing durable, personalized treatments and prevention strategies. The upcoming symposium and awards dinner in New York City will not only celebrate these scientific achievements but also galvanize further philanthropic support, ensuring that innovation in mental health research continues unabated.

Through visionary funding, robust peer review, and public engagement, the Brain & Behavior Research Foundation exemplifies a model for how science can drive societal progress in understanding and treating mental illnesses. The 2025 award recipients stand as beacons of this enduring endeavor, reminding us of the power of research to illuminate the shadowed corridors of the mind and improve the lives of millions worldwide.

Subject of Research: Mental health, schizophrenia, mood disorders, ADHD, cognitive neuroscience, psychiatric research

Article Title: Brain & Behavior Research Foundation Announces 2025 Outstanding Achievement Prizes in Mental Health

News Publication Date: Not specified

Web References: https://bbrfoundation.org/, https://bbrfoundation.org/event/international-mental-health-research-symposium

Image Credits: BBRF

Keywords: Mental health, psychiatry, schizophrenia research, mood disorders, ADHD, cognitive neuroscience, psychiatric science, brain research, neuropsychiatry, genetic analysis, neuroimaging, mental illness treatment

The Distinguished Investigator Grants program is made possible by the generous contributions of the WoodNext Foundation, which has notably committed $5 million to this cause over the span of five years. The foundation’s continued support reflects a dedication to the pursuit of knowledge and innovative solutions in the field of mental health. As mental illnesses affect a significant portion of the population, the role of these grants becomes even more crucial in fostering research that could change lives.

Jeffrey Borenstein, M.D., President and CEO of BBRF, emphasized the pressing need for continued research into mental health issues. He stated that these illnesses not only affect millions of individuals and families but also leave much to be discovered regarding the biology and potential treatments associated with them. By investing in high-risk yet promising research, the Distinguished Investigator Grants enable scientists to explore unconventional ideas that may lead to critical breakthroughs. It is this kind of support that can encourage scholars to step outside of traditional boundaries and confront complex issues head-on.

Nancy Chan, the Executive Director of the WoodNext Foundation, echoed these sentiments, expressing that their commitment to scientific research plays a pivotal role in enhancing understanding of mental health. She believes that empowering researchers to venture into uncharted territories is essential for advancing solutions for mental illness. The collaboration between BBRF and the WoodNext Foundation exemplifies a collective vision of fostering innovation in mental health research, which is vital for improving patient outcomes.

The ten distinguished recipients represent a wealth of knowledge and diversification in their research areas. They include esteemed professors and scholars from various research institutions across the United States and abroad. Each recipient was selected by a committee composed of 192 eminent experts in brain and behavior research, who scrutinized numerous proposals to identify the most promising projects. This thorough selection process ensures that the grants will be aligned with high standards of scientific inquiry.

Among the recipients, Eva S. Anton, Ph.D., from the University of North Carolina at Chapel Hill, is poised to unlock the secrets of neural signaling via the primary cilium. This crucial structure plays a vital role in neuronal communication, and Anton’s research aims to elucidate how dysfunctions in primary cilia signaling can disrupt neural circuits, potentially leading to significant mental health disorders.

Another notable recipient, Flavio Frohlich, Ph.D., also from the University of North Carolina at Chapel Hill, will focus on a pioneering neurostimulation approach. His project involves the development of a non-invasive technique designed to alleviate depressive symptoms among pregnant women. This innovative avenue of research reflects a significant intersection of mental health and maternal care, paving the way for improved psychological well-being during pregnancy.

Rita Goldstein, Ph.D., from the Icahn School of Medicine at Mount Sinai, is investigating opioid use disorder, a pressing public health crisis in many regions. Her research seeks to identify reliable behavioral markers associated with brain function changes during treatment. By employing a naturalistic approach, Goldstein aims to bring forth new insights that may significantly enhance therapeutic outcomes for those struggling with addiction.

Marek Kubicki, M.D., Ph.D., from Brigham and Women’s Hospital, Inc., will delve into the role of matrix metalloproteinase-9 (MMP-9) in schizophrenia. His exploration of this protein, involved in inflammation, aims to determine the potential for a groundbreaking biomarker that may assist in understanding the biological underpinnings of this complex disorder. The integration of advanced imaging techniques like PET scanning will provide valuable insights into the relationship between systemic inflammation and neurological health.

Christopher J. Pittenger, M.D., Ph.D., from Yale University, will extend our understanding of obsessive-compulsive disorder (OCD). He has recently identified a rare mutation linked with OCD, and his plan to replicate this mutation in animal models aims to reveal behavioral consequences that could translate into significant findings for human patients. This kind of genetic exploration is critical for unraveling the complexities of psychiatric conditions.

Sagiv Shifman, Ph.D., from The Hebrew University of Jerusalem, is investigating potential neuroprotective factors in females that may confer resistance against neurodevelopmental disorders. Utilizing mouse models, Shifman’s research will help clarify the genetic factors influencing the prevalence of these disorders and provide insight into the sex differences observed in neurodevelopmental conditions.

In a bold and innovative approach to psychedelic research, Doris Tsao, Ph.D., from the University of California, Berkeley, aims to explore the neural mechanisms by which these substances affect consciousness and perception. Her studies utilizing macaque monkeys seek to bridge the gap between subjective experiences of psychedelics and their objective neural correlates, thereby opening avenues for understanding the applications of psychedelics in therapeutic contexts.

Jared W. Young, Ph.D., from the University of California, San Diego, will pursue novel therapeutics tailored for cognitive deficits linked with bipolar disorder. This research focuses on presynaptic mechanisms that influence dopamine levels, targeting a specific receptor that could remediate the cognitive impairments experienced by bipolar patients. This approach exemplifies the need for therapies that specifically address the nuanced aspects of mental health disorders.

Venetia Zachariou, Ph.D., from Boston University, aims to unveil the neurochemical pathways connected with opioids to forge safer treatment options that minimize addiction risks while maximizing analgesic effects. Her work seeks to identify new signaling pathways that could lead to innovative interventions in pain management without the associated dangers of dependency.

Lastly, Stanislav S. Zakharenko, M.D., Ph.D., from St. Jude Children’s Research Hospital, seeks to elucidate the cellular mechanisms behind auditory hallucinations, a common symptom present in various psychiatric disorders. By studying genetic predictors of schizophrenia, Zakharenko hopes to uncover the neuronal processes involved in auditory perception, which could ultimately lead to improved diagnostic and therapeutic strategies.

The awards from BBRF’s Distinguished Investigator Grants program represent a pivotal moment in mental health research. By targeting areas that hold immense potential for advancement and maintaining a commitment to funding innovative and daring research, both BBRF and the WoodNext Foundation are fostering a powerful environment for scientific discovery. The collaborative efforts of these organizations are poised to reshape our understanding of mental illnesses while also inspiring a new generation of scientists to pursue uncharted territories in their research endeavors.

In conclusion, the 2025 Distinguished Investigator Grants not only reflect a significant investment in mental health research but also illuminate the collaborative spirit that drives innovation in this field. These grants will enable distinguished scientists to pursue groundbreaking research with the hope of discovering new therapies and solutions for individuals battling mental health disorders. As we look forward, the implications of this research could lead to transformative changes in how we understand, diagnose, and treat mental illnesses.

Subject of Research: Mental health disorders and innovative treatments
Article Title: BBRF Awards $1 Million in Grants to Pioneering Mental Health Researchers
News Publication Date: [Insert date]
Web References: [Insert URL]
References: [Insert any references]
Image Credits: Credit: BBRF

Keywords: mental health, research grants, neuroscience, schizophrenia, depression, opioid use disorder, psychedelic research, innovation, neurobiology, behavioral science.